Phenominer Database Results (9 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 28.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69436 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 7.5 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69437 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 17.6 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69408 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 33.0 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to38 days 69382 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 91.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69406 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 50.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69435 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 5.5 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days days 69383 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 17.4 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 38days 69407 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 33.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days 69379 892